Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $169.5 million.

  • TScan Therapeutics' Cash & Equivalents rose 2733.51% to $169.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.5 million, marking a year-over-year increase of 2733.51%. This contributed to the annual value of $178.7 million for FY2024, which is 3399.1% up from last year.
  • Latest data reveals that TScan Therapeutics reported Cash & Equivalents of $169.5 million as of Q3 2025, which was up 2733.51% from $169.4 million recorded in Q2 2025.
  • TScan Therapeutics' Cash & Equivalents' 5-year high stood at $242.2 million during Q2 2024, with a 5-year trough of $95.6 million in Q1 2023.
  • For the 5-year period, TScan Therapeutics' Cash & Equivalents averaged around $151.4 million, with its median value being $140.8 million (2022).
  • Per our database at Business Quant, TScan Therapeutics' Cash & Equivalents soared by 36392.75% in 2021 and then crashed by 3211.49% in 2023.
  • Quarter analysis of 5 years shows TScan Therapeutics' Cash & Equivalents stood at $161.4 million in 2021, then dropped by 25.64% to $120.0 million in 2022, then rose by 11.11% to $133.4 million in 2023, then skyrocketed by 33.99% to $178.7 million in 2024, then fell by 5.14% to $169.5 million in 2025.
  • Its Cash & Equivalents was $169.5 million in Q3 2025, compared to $169.4 million in Q2 2025 and $154.1 million in Q1 2025.